NCT03459508

Ocular Findings in Women With Primary Antiphospholipid Syndrome

Completed Last updated 24 October 2018

What this trial tests

trial testing Ophthalmological examination in Primary Antiphospholipid Syndrome in 50 participants. Completed in 23 October 2018.

Timeline

1 December 2017

Primary endpoint
10 October 2018

23 October 2018

Quick facts

Lead sponsor	Cairo University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	50
Start date	1 December 2017
Primary completion	10 October 2018
Estimated completion	23 October 2018
Sites	1 location across Egypt

Drugs / interventions tested

• Ophthalmological examination

Conditions studied

• Primary Antiphospholipid Syndrome — all drugs for Primary Antiphospholipid Syndrome →

Sponsor

Cairo University

Who can join

Adults 18 to 35, female only, with Primary Antiphospholipid Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Antiphospholipid antibody syndrome (APS) is an autoimmune disease characterized by systemic thrombosis and bad obstetric history. APS secondary to another medical disorder is the most common. Visual and ocular changes e.g. vaso-occlusive disease of retinal and choroidal vessels are found in patients with secondary APS. Patients with primary APS have also been reported to have ocular changes e.g. retinal vascular occlusion

The aim of our study to detect prevalence of ocular changes in women diagnosed with primary APS and correlation of these changes with adverse obstetric outcome. If a correlation is present, ocular findings in women with APS could be used in the future as a predictor for poor obstetric outcome.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.